Challenges and opportunities for developing selective carbonic anhydrase inhibitors and activators for vertebrate

Claudiu T Supuran1

  • 1Neurofarba Department, Pharmaceutical and Nutraceutical Section, University of Florence, Sesto Fiorentino (FI), Italy.

The Enzymes
|July 22, 2026
PubMed
Summary

Developing selective carbonic anhydrase inhibitors is crucial for treating diseases with fewer side effects. New chemotypes like coumarins show promise for isoform- and class-selective inhibition, advancing therapeutic applications.

Related Concept Videos